,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2013-01-23 09:14:00,St. Jude Medical 's ( STJ ) fourth-quarter adjusted earnings per share of 92 cents topped the Zacks Consensus Estimate by 2 cents and transcended the year-ago earnings of 86 cents.,0.9460543394088745,0.026235507801175117,0.02771008014678955,positive,0.9198188185691833
1,2013-01-23 09:14:00,The adjusted earnings exclude charges (of $75 million) related to restructuring activities of its business segments and centralization of certain support functions.,0.01210238691419363,0.03262849152088165,0.9552691578865051,neutral,-0.020526103675365448
2,2013-01-23 09:14:00,Costs related to impairment of intangibles and inventory write-off for suspension of certain Cardiovascular and Ablation Technologies Division (CATD) offerings were also excluded.,0.024856312200427055,0.14438258111476898,0.8307611346244812,neutral,-0.11952626705169678
3,2013-01-23 09:14:00,"Adjusted earnings also excluded certain income tax-related expenses, and legal and other charges associated with field actions in the Implantable Electronic Systems Division (IESD).",0.021445736289024353,0.07702994346618652,0.9015243053436279,neutral,-0.05558420717716217
4,2013-01-23 09:14:00,"However, it includes an income tax benefit of $6 million from the federal research and development tax credit.",0.056290410459041595,0.008299289271235466,0.9354103207588196,neutral,0.04799111932516098
5,2013-01-23 09:14:00,"Profit (as reported) for the fourth quarter dropped 4% year over year to $120 million (or 39 cents a share), as controlled operating expenses were dampened by sluggish sales and a difficult Med-Tech environment.",0.01761602610349655,0.9736986756324768,0.008685187436640263,negative,-0.9560826420783997
6,2013-01-23 09:14:00,"For 2012, adjusted earnings of $3.48 a share beat the Zacks Consensus Estimate by 3 cents and exceeded the year-ago earnings of $3.28 a share.",0.9388552904129028,0.03848440572619438,0.022660301998257637,positive,0.9003708958625793
7,2013-01-23 09:14:00,Profit declined roughly 8% year over year to $752 million or $2.39 a share.,0.017515482380986214,0.9702857136726379,0.012198856100440025,negative,-0.9527702331542969
8,2013-01-23 09:14:00,"The Minnesota-based medical technology giant noted that only the Atrial Fibrillation business is growing at a healthy pace and the implantable cardioverter defibrillator (ICD) has not lost market share, despite the manufacturing issues of the Riata/Durata leads.",0.15873761475086212,0.7766868472099304,0.06457548588514328,negative,-0.6179492473602295
9,2013-01-23 09:14:00,"Revenues dropped 2% (down 1% in constant currency) year over year to $1,372 million, just ahead of the Zacks Consensus Estimate of $1,370 million.",0.01669231243431568,0.9738448262214661,0.009462838061153889,negative,-0.9571524858474731
10,2013-01-23 09:14:00,"All segments reported disappointing results, especially Cardiac Rhythm Management (CRM) and Neuromodulation units, except the Atrial Fibrillation (AF) business.",0.018393563106656075,0.9525684118270874,0.029038002714514732,negative,-0.9341748356819153
11,2013-01-23 09:14:00,"For the full year, sales also declined 2% (up 1% in constant currency) year over year to $5,503 million, modestly beating the Zacks Consensus Estimate of $5,501 million.",0.01939420774579048,0.9719813466072083,0.008624467998743057,negative,-0.9525871276855469
12,2013-01-23 09:14:00,"Foreign currency fluctuations lowered revenues by roughly $23 million and $137 million in the fourth quarter and 2012, respectively.",0.017264539375901222,0.9714156985282898,0.011319737881422043,negative,-0.9541511535644531
13,2013-01-23 09:14:00,"Revenues from the CRM division, St. Jude's mainstay, fell 6% (down 5% in constant currency) year over year to $682 million, indicating sustained softness in the CRM market.",0.017848247662186623,0.9727292656898499,0.00942249596118927,negative,-0.9548810124397278
14,2013-01-23 09:14:00,ICD revenues slid 3% (down 2% in constant currency) to $422 million and pacemaker sales plunged 11% (down 9% in constant currency) to $260 million.,0.0163371954113245,0.9734405279159546,0.010222233831882477,negative,-0.9571033120155334
15,2013-01-23 09:14:00,"A still choppy U.S. defibrillator market remains an overhang on St. Jude and its peers Medtronic ( MDT ) and Boston Scientific ( BSX ), as reflected by sustained implant volume pressure.",0.053442347794771194,0.8965702652931213,0.04998748004436493,negative,-0.8431279063224792
16,2013-01-23 09:14:00,"ICD volume growth has been hindered by a number of factors, including the Food and Drug Administration (FDA) warning letter.",0.019466711208224297,0.9669252038002014,0.013608133420348167,negative,-0.9474585056304932
17,2013-01-23 09:14:00,"On a positive note, Atrial Fibrillation revenues climbed 10% (up 11% in constant currency) year over year to $239 million.",0.9589542746543884,0.020246895030140877,0.020798785611987114,positive,0.9387073516845703
18,2013-01-23 09:14:00,"However, Neuromodulation sales dropped 7% (down 6% in constant currency) to $113 million.",0.01667078770697117,0.9741621017456055,0.009167145937681198,negative,-0.9574913382530212
19,2013-01-23 09:14:00,Revenues from the Cardiovascular franchise remained flat at $338 million.,0.01587405428290367,0.9147908091545105,0.06933511793613434,negative,-0.8989167809486389
20,2013-01-23 09:14:00,"Within Cardiovascular, vascular products sales dipped 2% to $186 million.",0.01675509475171566,0.9737547636032104,0.009490166790783405,negative,-0.956999659538269
21,2013-01-23 09:14:00,Structural heart product revenues were flat at $152 million.,0.016707902774214745,0.8899879455566406,0.09330416470766068,negative,-0.8732800483703613
22,2013-01-23 09:14:00,Gross margin decreased to 69.5% from 71.4% a year ago.,0.018476003780961037,0.9731255769729614,0.008398456498980522,negative,-0.9546495676040649
23,2013-01-23 09:14:00,"Selling, general and administrative expenses, as a percentage of sales, fell to 32.9% from 39.2% a year-ago.",0.018784010782837868,0.9734583497047424,0.0077576711773872375,negative,-0.9546743631362915
24,2013-01-23 09:14:00,Research and development expenses (as a percentage of sales) edged down to 11.5% from 12.6%.,0.019140876829624176,0.9722887873649597,0.008570305071771145,negative,-0.9531478881835938
25,2013-01-23 09:14:00,"However, it is worthwhile to note that operating margins increased to 16.4% from 11.2% a year ago, on the back of controlled expenses.",0.9578493237495422,0.02757873386144638,0.014571871608495712,positive,0.9302706122398376
26,2013-01-23 09:14:00,"St. Jude exited the fourth quarter of 2012 with cash and cash equivalents of $1,194 million, a year over year increase of roughly 21.1%.",0.9401682615280151,0.016219301149249077,0.04361247271299362,positive,0.9239489436149597
27,2013-01-23 09:14:00,"Long-term debt decreased 6% year over year to $2,713 million.",0.018811065703630447,0.9728067517280579,0.008382188156247139,negative,-0.9539957046508789
28,2013-01-23 09:14:00,St. Jude has provided its earnings forecast for the first quarter as well as 2013.,0.02935369871556759,0.011584720574319363,0.9590616226196289,neutral,0.0177689790725708
29,2013-01-23 09:14:00,The company expects adjusted earnings for the year in the band of $3.68-$3.73 per share.,0.12515534460544586,0.013807976618409157,0.8610367178916931,neutral,0.11134736984968185
30,2013-01-23 09:14:00,"For the first quarter, it envisions adjusted earnings in the range of 91-93 cents a share.",0.10638868808746338,0.006875326856970787,0.8867360353469849,neutral,0.09951335936784744
31,2013-01-23 09:14:00,"The current Zacks Consensus Estimates for the first quarter and 2012 are 89 cents and $3.64, respectively.",0.01263937633484602,0.02775605022907257,0.9596045613288879,neutral,-0.015116673894226551
32,2013-01-23 09:14:00,"St. Jude, with a market cap of $12.23 billion, is a leading medical device manufacturer maintaining a solid rate of growth over the past decade.",0.9274808764457703,0.013438873924314976,0.05908021703362465,positive,0.9140419960021973
33,2013-01-23 09:14:00,We are impressed by the company's efforts in leveraging its margins by undertaking various restructuring initiatives and controlling expenses.,0.8798370361328125,0.011669949628412724,0.10849295556545258,positive,0.8681671023368835
34,2013-01-23 09:14:00,"However, competitive pressures and a sluggish CRM market, given the ongoing difficult macroeconomic conditions, continue to be a drag on the company's results.",0.035191141068935394,0.8170286417007446,0.1477801650762558,negative,-0.781837522983551
35,2013-01-23 09:14:00,St. Jude currently carries a Zacks Rank #3 (Hold).,0.03989259898662567,0.020126808434724808,0.9399806261062622,neutral,0.019765790551900864
36,2013-01-23 09:14:00,"Medical products companies such as Unilife Corporation ( UNIS ), which carries a Zacks Rank #1 (Strong Buy), is expected to do well.",0.9427096843719482,0.017257209867239,0.04003307595849037,positive,0.925452470779419
37,2013-01-23 09:14:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
38,2013-01-23 09:14:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
